See What HealthDay Can Do For You
Contact Us

ACR: Ankylosing Spondylitis Protein Marker Identified

New discovery could change approach to treatment

WEDNESDAY, Nov. 15 (HealthDay News) -- In ankylosing spondylitis patients, the protein marker matrix metalloproteinase 3 (MMP3) is a significant predictor of joint damage, according to a paper presented at the American College of Rheumatology Annual Scientific Meeting held Nov. 10-15 in Washington, D.C.

Walter P. Maksymowych, M.D., of the University of Alberta in Edmonton, Canada, and colleagues conducted a study of eight serological biomarkers already implicated as independent predictors of rheumatoid arthritis, and assembled complete data on 100 patients.

Only two biomarkers -- human cartilage glycoprotein-39 (YKL-40) and MMP3 -- had a weak to moderate correlation with two-year progression of ankylosing spondylitis, and only MMP3 remained as a marker with significant association with two-year progression after adjustment for sex, age and disease duration. The association was strongest in those who had pre-existing radiographic damage.

"With this biomarker we can now target patients at highest risk for joint damage and in greatest need for effective therapy," Maksymowych said in a statement. "Being able to predict disease activity and damage in ankylosing spondylitis patients can lead to more aggressive treatment when the disease is active and more aggressive."

Abstract

Physician's Briefing
undefined
undefinedundefined